Organisation paid for research Program year 2025 Source: CMS Open Payments

Westside Aesthetics

Neither a doctor nor a teaching hospital

Research payments

$92,607

14 payments

Through program year 2025, Westside Aesthetics is reported as receiving $92,607 in research payments, across 14 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$917	1
2023	Research	$15,990	3
2022	Research	$13,100	2
2020	Research	$225	1
2019	Research	$62,375	7

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $62,600 8 payments
AbbVie, Inc. $30,007 6 payments

Studies the money was for Research payments · program years 2019–2025

A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition $61,674 6 payments
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $11,859 1 payment
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL. $8,417 2 payments
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study across approximately 35 sites in USA, Belgium, Canada, Germany, Russia, and the UK. $7,574 1 payment
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $1,241 1 payment
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $917 1 payment
BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 2b, Multicenter, Randomized, Double Blind, Multi-Dose, Placebo-Controlled Study $701 1 payment
BOTOX (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double Blind, Multi-Dose, Placebo-Controlled Study $225 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.